EQS-News: Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care

By Johnny Rice Benzinga

DETROIT, MICHIGAN - March 19, 2025 (NEWMEDIAWIRE) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzinga’s All-Access.

GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The company’s vision is to create a future where diabetes management is automatic and inconspicuous, empowering people to live boldly and unapologetically.

Learn more here:

https://www.youtube.com/watch?v=xjn-_aLseTc&feature=youtu.be 

Featured photo by Towfiqu barbhuiya on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

News Source: Benzinga